Treatment milestones for Aortech and Kyowa Kirin
Aortech investment shows ‘growing confidence’ (pic: Aortech)
Scottish healthcare companies have unveiled significant progress in the development of new treatments.
AorTech International, an AIM-quoted business based in Dundee, said performance of its heart valve manufacturing technology has improved through the design phase.
It said costs are being partly financed through a grant from Scottish Enterprise, although its products are manufactured by Biomerics in Utah, US.
AorTech chairman Bill Brown, said: “This investment demonstrates the growing confidence in both the design of, and the novel manufacturing process for, the polymeric heart valve and we wish to thank Scottish Enterprise for their help and assistance towards this project.”
He added: “Through the design phase, our team has significantly improved valve performance and we are now targeting step changes in consistency and quality.”
Kyowa Kirin, the Borders business formerly known as ProStrakan, has secured marketing validation for its treatment for Parkinson’s disease from the European Medicines Agency (EMA).
Abdul Mullick, president of Kyowa Kirin International, said: “Parkinson’s disease is the fastest growing neurological disorder in the world in terms of prevalence, disability and deaths.
“There is significant need for new treatments for this debilitating condition. We are very excited about the possibility of bringing a new medicine to patients that works in a different way from current therapies.
“We look forward to working with the EMA during the review process.”